We develop neuroimaging and genetic solutions for the early detection and prediction of Alzheimer’s disease.
Early detection matters
Neurozen is dedicated to developing advanced, deep learning-enabled neuroimaging and genetic solutions for the risk assessment and early detection of Alzheimer’s disease.
Risk assessment and early detection are crucial to helping target the disease before irreversible brain damage or cognitive decline has occurred.
Our mission is to provide innovative, quality clinical tools to predict, quantify, and monitor neurodegeneration so that physicians can be more confident in making important clinical decisions and people can enjoy a higher quality of life.
AI-powered neuroimaging and genetics
LARGEST DEMENTIA COHORT IN ASIA
Neurozen has an exclusive license to the largest Asian dementia cohort organized by the National Research Center for Dementia (NRCD).
MULTIMODAL DATA
This cohort is an ongoing, longitudinal, multicenter study collecting clinical, neuropsychological, imaging (MRI and PET) and genomic data.
Backed by Science
We work with a diverse network of neuroscientists, radiologists, bioinformatics specialists, and dementia experts to develop unique and effective solutions for Alzheimer's disease.
Deep learning technologies
Using deep learning technology, we have developed a normative database to empower accurate comparisons and more informed diagnoses.
Our Products and Services
AlzgenAI
Korean genomics-based prediction of
High risk individual of Alzheimer’s disease
KCDC genetic test approved
Service launch in June 2022
MemoAI
Digitalized visuospatial cognitive test
AI-based automatic evaluation
Beta version launch in July 2022
Service launch in October 2022
NeuroAI
MRI and APOE genotype-based
Amyloid PET positivity prediction
In clinical trial (KFDA medical device level 3)
Expect to be approved in 2022
Quantitative brain imaging analysis for assessment of brain atrophy
- Neuro I Brain Image Quantitative Analysis System
- Neuro AI Clinical Decision Support System
Detailed genetic analysis for accurate Alzheimer's disease risk assessment
- APOplus Genetic Testing Service
- AlzgenAI Alzheimer’s Risk Assessment Service
Our Leadership
Our News & Posts
Subscribe to
our newsletter
Get product and service updates, important events, and promotions straight to your inbox.